BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

NEW YORK , Feb. 17, 2024 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and October 13, 2023, both dates inclusive (the "Class Period"), of the important March 12, 2024 lead plaintiff deadline. SO WHAT: If you purchased BioNTech securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, LEADING INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX

RADNOR, Pa. , Feb. 17, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against BioNTech SE ("BioNTech") (NASDAQ: BNTX).

Kessler Topaz Meltzer & Check, LLP Reminds BNTX Investors of March 12, 2024 Deadline in Securities Fraud Class Action against of BioNTech SE (BNTX) and Urges Investors with Substantial Losses to Contact the Firm

NEW YORK, NY / ACCESSWIRE / February 14, 2024 / If you suffered a loss on your BioNTech SE (NASDAQ:BNTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biontech-lawsuit-submission-form?prid=67064&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 12, 2024 in BioNTech Lawsuit – BNTX

LOS ANGELES, CA / ACCESSWIRE / February 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioNTech SE ("BioNTech" or "the Company") (NASDAQ:BNTX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 30, 2022 and October 13, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before March 12, 2024.

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in BioNTech SE with Losses of $100,000 to Contact the Firm

NEW YORK, NY / ACCESSWIRE / February 12, 2024 / If you suffered a loss on your BioNTech SE (NASDAQ:BNTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biontech-lawsuit-submission-form?prid=66792&wire=1 or contact Joseph E. Levi, Esq.

Investors Who Lost Money on BioNTech SE(BNTX) Should Contact Levi & Korsinsky About Pending Class Action - BNTX

NEW YORK, NY / ACCESSWIRE / February 11, 2024 / If you suffered a loss on your BioNTech SE (NASDAQ:BNTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biontech-lawsuit-submission-form?prid=66687&wire=1 or contact Joseph E. Levi, Esq.

BioNTech SE Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 12, 2024 to Discuss Your Rights – BNTX

NEW YORK, NY / ACCESSWIRE / February 11, 2024 / If you suffered a loss on your BioNTech SE (NASDAQ:BNTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biontech-lawsuit-submission-form?prid=66668&wire=1 or contact Joseph E. Levi, Esq.

Class Action Filed Against BioNTech SE (BNTX) Seeking Recovery for Investors – Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / February 11, 2024 / If you suffered a loss on your BioNTech SE (NASDAQ:BNTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biontech-lawsuit-submission-form?prid=66677&wire=1 or contact Joseph E. Levi, Esq.

Class Action Filed Against BioNTech SE (BNTX) - March 12, 2024 Deadline to Join – Contact Levi & Korsinsky

NEW YORK , Feb. 10, 2024 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and October 13, 2023, both dates inclusive (the "Class Period"), of the important March 12, 2024 lead plaintiff deadline. SO WHAT: If you purchased BioNTech securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A TOP RANKED LAW FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX

LOS ANGELES, CA / ACCESSWIRE / February 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioNTech SE ("BioNTech" or "the Company") (NASDAQ:BNTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 30, 2022 and October 13, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before March 12, 2024.

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in BioNTech SE with Losses of $100,000 to Contact the Firm

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioNTech To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 investing in BioNTech stock or options between March 30, 2022 and October 13, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/BNTX.

BIONTECH INVESTOR DEADLINE APPROACHING

NEW YORK , Feb. 9, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of BioNTech SE. Shareholders who purchased shares of BNTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of BioNTech SE(BNTX) Shareholders

RADNOR, Pa. , Feb. 8, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against BioNTech SE ("BioNTech") (NASDAQ: BNTX).

Kessler Topaz Meltzer & Check, LLP Reminds BioNTech SE Investors of Important Deadline in Securities Fraud Class Action Lawsuit and Encourages Investors to Contact the Firm

NEW YORK , Feb. 8, 2024 /PRNewswire/ -- Attention BioNTech SE ("BioNTech") (NASDAQ: BNTX) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between March 30, 2022 and October 13, 2023. If you suffered a loss on your investment in BioNTech, contact us about potential recovery by using the link below.

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind BioNTech Investors of a Lead Plaintiff Deadline of March 12, 2024

LOS ANGELES, CA / ACCESSWIRE / February 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioNTech SE ("BioNTech" or "the Company") (NASDAQ:BNTX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 30, 2022 and October 13, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before March 12, 2024.

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in BioNTech SE with Losses of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / February 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioNTech SE ("BioNTech" or "the Company") (NASDAQ:BNTX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 30, 2022 and October 13, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before March 12, 2024.

IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in BioNTech SE with Losses of $100,000 to Contact the Firm

NEW YORK , Feb. 6, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in BioNTech SE ("BioNTech" or the "Company") (NASDAQ: BNTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of BioNTech investors who were adversely affected by alleged securities fraud between March 30, 2022 and October 13, 2023.

SHAREHOLDER ALERT: Levi & Korsinsky Notifies BioNTech SE(BNTX) Investors of a Class Action Lawsuit and Upcoming Deadline

LOS ANGELES, CA / ACCESSWIRE / February 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioNTech SE ("BioNTech" or "the Company") (NASDAQ: BNTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 30, 2022 and October 13, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before March 12, 2024.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in BioNTech SE with Losses of $100,000 to Contact the Firm

Eli Lilly

Merck

The pharma industry has developed some real blockbusters between novel vaccines and weight loss drugs over the past few years. This has increasingly led investors to view pharma stocks as a promising growth industry after years of underperformance, but many are top pharma stocks to sell.

3 Pharma Stocks to Sell in February Before They Crash and Burn

BIONTECH SHAREHOLDER ACTION REMINDER

LOS ANGELES, CA / ACCESSWIRE / February 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioNTech SE ("BioNTech" or "the Company") (NASDAQ:BNTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 30, 2022 and October 13, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before March 12, 2024.

SHAREHOLDER ACTION DEADLINE: The Schall Law Firm Encourages Investors in BioNTech SE with Losses of $100,000 to Contact the Firm

NEW YORK , Feb. 2, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of BioNTech SE. Shareholders who purchased shares of BNTX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of BioNTech SE of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 12, 2024 - (NASDAQ: BNTX)

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming March 12, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX) securities between March 30, 2022 and October 13, 2023, inclusive (the “Class Period”). If you suffered a loss on your BioNTech investments or would like to inquire about potentially pursuing claim.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioNTech SE (BNTX)

Designation is based on preliminary safety and efficacy data from an ongoing Phase 1/2 trial in patients with platinum-resistant ovarian epithelial cancer, fallopian tube, or primary peritoneal cancer 1 Fast Track designation can facilitate the development and expedite the regulatory review of BNT325/DB-1305  Ovarian cancer is the fourth most common gynecological tumor type 2 with over 300,000 cases diagnosed globally each year 3 ; over 90% of ovarian tumors arise from epithelial cells, including the epithelial tissue of the ovary, the lining of a fallopian tube or the peritoneum 4   MAINZ, Germany and SHANGHAI, China, January 31, 2024 – BioNTech SE  (Nasdaq: BNTX, “BioNTech”) and Duality Biologics (Suzhou) Co., Ltd. (“DualityBio”) today announced that the U.S. Food and Drug Administration (“FDA”) granted Fast Track designation for BNT325/DB-1305 for the treatment of patients with platinum-resistant ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.

BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305

RADNOR, Pa. , Jan. 30, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed against BioNTech SE ("BioNTech") (NASDAQ: BNTX).

BioNTech SE (BNTX) Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds BNTX Investors of Securities Fraud Class Action Lawsuit Filed On Their Behalf

News for BioNTech SE Stock (BNTX)